

# Subject Index

- A**
- Aborigine, 13
    - desire for sweet tastes, 52
    - diabetes, 148
    - diet, 148
    - public health, 148
  - Acesulfame-K, 47
  - N-Acetylgalactosaminide residue, 121–123
  - Adaptive thermogenesis, 180–183
  - Adenosine triphosphate, 267
  - Adipose tissue, insulin, 195
  - Adult-type hypolactasia, 93
  - Adult-type lactose intolerance, 93
  - Age, obesity, 180
  - AH-B hypothesis, 55
    - psychophysical data, 61
  - Alcohol
    - production, 26
    - sucrose, 148
  - Alitame, 47
  - Amiloride, 62–63
  - Amylo-1,6-glycosidase deficiency
    - clinical features, 256–257
    - diagnosis, 257
    - functional tests, 257
    - genetic heterogeneity, 257
    - historical aspects, 256
    - treatment, 257
  - Angiotensin-converting enzyme, celiac disease, 113
  - Animal, sugar preference, 12
  - Appetite, 179
    - control in obesity, 188
    - loss, 179
  - Apple juice, fructose, 80
  - Artificial sweetener, 25
    - obesity, 188–189
    - weight gain, 52
  - Asian Indian
    - hyperinsulinemia, 211
    - obesity, 211
  - Aspartame, 46–47
    - metabolism, 46
  - Atherosclerosis
    - fat, 151
    - sucrose, 151
  - Athlete's diet, 267–276. *See also* Diet anorexia nervosa, 277
    - athlete's health beliefs, 272–273
    - calcium, 273
    - carbohydrate, 267–274
    - dietary fiber, 273
    - endurance athletes, 277
    - fat, 270, 271
    - gender differences, 274–275
    - glucose, 268
    - glucose polymer products, 278
    - iron, 273
    - pre-event meals, 278
    - sugar, 272
    - vitamin, 273
    - zinc, 273
  - Australia
    - development barriers, 12
    - sugar production, 29
  - Autophagy, 263
- B**
- Background diet, 150
  - Beet sugar, 18
    - hunger, 12
  - Behavioral therapy
    - diet, 186–187
    - obesity, 186–187
  - Body composition, 195
  - Body mass index, 183–184
  - Bone marrow transplantation, 129
  - Branching enzyme deficiency
    - clinical features, 257–258
    - diagnosis, 258
    - glycogen abnormality, 258

Branching enzyme deficiency (*contd.*)  
 historical aspects, 257–258  
 pathogenesis, 258  
 treatment, 258

Brazil, ethanol, 18–19, 26, 28

Breast feeding, 166–167. *See also* Human milk  
 sugar-induced diarrhea, 230

Breast milk allergy, 231

Brush-border  $\alpha$ -glucosidase, 97

Brush-border  $\beta$ -glucosidase, 97

Brush-border hydrolase, 103–109  
 biosynthesis, 106–108  
 congenital disorder, 106–108  
 congenital sucrase-isomaltase deficiency, 106–107  
 intracellular processing, 106–108  
 lactase deficiency, 107  
 mucosal injury, 108

Brush-border membrane, transport protein, 84

Brush-border transporter  
 dietary carbohydrate levels, 84–85  
 sugar, 84

Brussels Sugar Convention of 1902, 23

Bulk effect, 161

## C

Calcium, athlete's diet, 273

Caloric sweetener, 25

cAMP transport, sweetness, 62–64

Cancer, short-chain fatty acid, 161–162

Cane sugar, hunger, 12

Carbohydrate  
 athlete's diet, 267–274  
 complex, 154  
 consumption changes, 133  
 glycogen stores, 269  
 human milk, 235  
 insulin, 194  
 metabolism, 157–158  
 normal consumption, 269–272  
 undigestible, cancer development, 161

Carbohydrate loading, 268–269

Carbohydrate metabolism  
 disorders, 213–220  
 non-insulin-dependent diabetes, 172–173

Carbohydrate stores, 268

Celiac disease  
 angiotensin-converting enzyme, 113  
 glucose, 73–74  
 lactose, 232

Chadbourne Agreement of 1931, 23

Cholecystokinin, satiety, 196

Cholesterol, sucrose, 140

Cholesterol metabolism, dietary fiber, 162–163

Colon, fructose, 81

Colon tumor, dietary fiber, 161

Congenital alactasia, 111

Congenital lactase deficiency, 231

Congenital sucrase-isomaltase deficiency,  
 brush-border hydrolase, 106–107

Corn industry, 31–32

Corn syrup sugar, 14

Coronary artery disease, plasma triglyceride, 169

Coronary heart disease, sucrose, 150

Crohn's disease, 168

Cyclamate, 46

Cystic fibrosis, glucose, 74

## D

Date sugar, 14

Dental caries, 37, 39

Dermatan sulfate  
 degradation enzymes, 121–123  
 stepwise exoenzyme degradation, 116–117, 120

Developing population  
 glucose intolerance, 206–207  
 hyperinsulinemia, 206–207  
 hyperlipidemia, 206–207  
 hypertension, 206–207  
 non-insulin-dependent diabetes mellitus  
 age, 201–202  
 child, 210  
 dietary change, 202–203  
 evolutionary and anthropological perspective, 199  
 genetics, 200–201  
 glycemic index, 209–210  
 incidence, 197–207, 198  
 increased longevity, 201–202  
 lifestyle, 201–206

- obesity, 203–204
- onset, 210
- physical activity, 204–205
- risk factors, 201–206
- stress, 206
- thrifty gene hypothesis, 209
- thrifty genotype, 199, 200
- obesity, 206–207
- Dextrose, 40
  - sweetness, 36
- Diabetes. *See also* Non-insulin-dependent diabetes mellitus
  - aborigine, 148
  - Eskimo, 211
  - peripheral neuropathy, 67
  - Pima, 210, 211
  - sucrose, 142–143
  - sweet taste, 66
- Diarrhea, sugar-induced, 221–228
- Diet. *See also* Athlete's diet
  - agriculturalist, 202–203
  - behavioral therapy, 186–187
  - fat content, 66
  - hunter-gatherer, 202–203
  - modern, 202–203
  - obesity, 179–192
  - peasant agriculturalist, 202–203
  - selection, 183–184
  - sensory properties, 66
- Dietary fiber, 153–155
  - athlete's diet, 273
  - cholesterol metabolism, 162–163
  - colon tumor, 161
  - large bowel, 161
  - obesity, 187–188
  - physiological properties, 153–155
  - sources, 154
- Dietary guidelines, 13–14
- Dihydrochalcone, 48
- Dihydroxyacetone phosphate, 134–135
- Disaccharidase
  - disaccharide, 104
  - hormonal control, 132
  - oligopeptide, 104
  - oligosaccharide, 104
- Disaccharidase activity, rate limiting, 76–77
- Disaccharide, 36–40
  - absorption, 76–77
  - digestion and absorption defects, 216–219
    - disaccharidase, 104
  - Disaccharide deficiency, causes, 222, 223
  - Disaccharide hydrolysis, monosaccharide absorption, 131–132
  - Disaccharide intolerance, causes, 222, 223
  - Drug therapy, obesity, 190
- E**
- Eating pattern, obesity, 189–190
- Energy balance
  - assessment, 183
  - sources of error, 183
  - obesity, 180–182
- Enteropeptidase, 111
- Enzyme regulation, biophysical aspects, 103–109
- Enzyme replacement therapy, 128, 264
- Eskimo
  - diabetes, 211
  - sucrase, 13
- Essential benign fructosuria, 216
- Ethanol, 26
  - Brazil, 18–19, 26, 28
  - as strategic matter, 28
- European Community, 31, 32
- Exercise
  - developing populations, 204–205
  - non-insulin-dependent diabetes mellitus, 204–205
  - obesity, 182, 185
- F**
- Fat
  - atherosclerosis, 151
  - athlete's diet, 270, 271
  - insulin resistance, 176
- Fatty acid, 158–159
  - mucosal cell proliferation, 160
- Final lactase-phlorizin-hydrolase, 95
- Flavor, 188
- Food intake restriction, 181
- Food interaction thermogenic effects, obesity, 187
- Food osmolarity, 195
- Food therapy, obesity, 187

- Free fatty acid, 195
- Fructokinase  
  intestine, 134  
  kidney, 134
- Fructolysis, 134–137  
  lipogenic impact, 137–139
- Fructose, 1  
  absorption, glucose stimulation, 76  
  apple juice, 80  
  biochemistry, 151  
  breath hydrogen method, 80  
  colon, 81  
  diabetic complication, 143  
  diffusion kinetics, 71, 75  
  dose-response, 149  
  gastric emptying rate, 52  
  glucose conversion, 75  
  glucose-facilitated absorption, 80  
  glycine, 81  
  human absorption, 75–76  
  hypertriglyceridemia, 148  
  incomplete absorption, 239  
  increased breath hydrogen, 239  
  insulin resistance, 141–142  
  lactic acid conversion, 75  
  liver, 133–134  
  monosaccharide intake, 69  
  as nutrients, 132–133  
  special transport system, 76  
  sweetness, 36  
  uric acid, 149  
  water absorption, 81
- D-Fructose, 40–41
- Fructose intolerance, 216
- Fructose metabolism, 133–137  
  disorders, 216
- Fructose transporter, 84  
  sucrose diet, 91
- Fructosuria, 216
- G**
- Galactose, human absorption, 70–74  
  brush-border carrier protein, 70  
  carrier number, 72–73  
  disease changes, 73–74  
  intestine section, 70–72
- Galactose malabsorption, 78
- Galactose transport, newborn, 92
- Galactosemia, 214–215  
  dietary treatment, 231
- $\alpha$ -Galactosidase, 156
- Gastric emptying, 195
- Glucosamine-6-sulfatase, 125
- Glucose, 80  
  athlete's diet, 268  
  celiac disease, 73–74  
  cystic fibrosis, 74  
  gastric emptying rate, 52  
  human absorption, 70–74  
    brush-border carrier protein, 70  
    carrier number, 72–73  
    disease changes, 73–74  
    intestine section, 70–72  
  intestinal  $K_m$  electrical measurement, 72  
  jejunum, 71  
  metabolism, 133–137  
  small bowel, 70–71  
  transmucosal potential, 72, 73
- D-Glucose, 40
- Glucose-6-phosphatase, kidney, 264
- Glucose-6-phosphatase deficiency  
  biochemical defect, 253  
  clinical features, 253–254  
  functional tests, 253–254  
  historical aspects, 251–252  
  hyperlipidemia, 263  
  physiopathology, 253  
  treatment, 254
- Glucose-galactose malabsorption, 214
- Glucose malabsorption, 78
- Glucose transport  
  high-carbohydrate diet, 91  
  newborn, 92
- Glucose transporter, 84
- Glucose uptake, 92
- Glucuronate-2-sulfatase, 121
- Glucuronic acid, 121
- Glyceraldehyde phosphate, 134–135
- Glycine, fructose, 81
- Glycogen, 249
- Glycogen metabolism  
  liver, 249  
  muscle, 249
- Glycogen storage disease, 249–261

enzyme therapy, 264  
tissue glycogen content, 251  
Glycogen stores, 268  
  carbohydrate, 269  
Glycosaminoglycan, 115  
Glycosaminoglycan degradation, 115–126  
Glycyrrhizin, 48  
Government sugar subsidy, 19, 31  
Greenland Eskimo, sucrase, 13

**H**

Heparan sulfate  
  biosynthesis, 115, 117  
  function, 128  
  production, 128  
Heparan sulfate degradation, enzymes,  
  115–121  
Heparan sulfate oligosaccharide,  
  exoenzyme degradation, 116,  
  118–119  
Heparan sulfate proteoglycans, 115, 117  
Hepatic steatosis, 149  
Hepatomegaly glycogen storage disease  
  clinical features, 250  
  laboratory features, 250  
Hereditary fructose intolerance, 216  
  differential diagnosis, 218  
Hereditary sucrase-isomaltase deficiency,  
  217–219  
  differential diagnosis, 218  
  types, 218, 219  
High-carbohydrate diet, glucose  
  transport, 91  
High-fructose corn syrup, 28  
  commercial crystallization, 28  
  resource requirements, 31  
  sweetness, 36  
Honey, 14  
Human milk. *See also* Breast feeding  
  carbohydrate, 235  
  carbohydrate patterns, 234  
  metabolism, 235–236  
  oligosaccharide, 238  
  physiological role, 235–236  
  qualitative studies, 234–235  
  quantitative studies, 234–235  
  sugar, 233–238  
Hunger, 179  
  beet sugar, 12  
  cane sugar, 12  
Hurler disease, 129  
Hurler/Scheie disease, 129  
Hydrogenated glucose syrup, 45  
Hyperactivity, sucrose, 66  
Hyperinsulinemia, 169  
  Asian Indian, 211  
  independent of age, 210–211  
  insulin resistance, 170–171  
  obesity, 194  
  very low density lipoprotein, 169  
Hyperlipidemia  
  glucose-6-phosphatase deficiency, 263  
  sucrose, 139–141  
Hypertension  
  insulin resistance, 177  
  New Guinea, 211–212  
  Western Africa, 211–212  
Hypertriglyceridemia  
  fructose, 148  
  insulin resistance, 171–172, 177  
  sucrose, 171–172  
Hyperuricemia, 149  
Hypoglycemia, raw starch, 263  
Hypolactasia, 93, 241–242  
  clinical consequences, 243  
  nutritional consequences, 243

**I**

Idose, 130  
Iduronate, 130  
Iduronate-2-sulfatase, 121  
Iduronic acid, 121, 130  
 $\alpha$ -L-Iduronidase deficiency, 129  
India  
  sugar consumption, 28–29  
  sugar production, 28–29  
Insulin  
  adipose tissue, 195  
  carbohydrate, 194  
Insulin resistance, 169–174  
  fat, 176  
  fructose, 141–142  
  hyperinsulinemia, 170–171  
  hypertension, 177

- Insulin resistance (*contd.*)  
   hypertriglyceridemia, 171–172, 177  
   non-insulin-dependent diabetes,  
     172–174  
   obesity, 177  
   sucrose, 141–142, 176  
 Insulin sensitivity, bimodality, 177  
 International Sugar Agreement, 23–25  
 Intestinal disaccharidase, genetic defects,  
   103  
 Intestinal epithelial cell, 104  
 Intestinal flora, 166  
 Intestinal hyperplasia, small bowel  
   resection, 92  
 Intestinal sugar transport  
   biology, 83–90  
   fetal development, 91  
   metabolic rate, 87  
   newborn, 91  
   ontogenetic development, 86–88  
   species variation, 87, 88  
 Intestine, fructokinase, 134  
 Invert sugar, sweetness, 36  
 Iron, athlete's diet, 273  
 Isomalt, 45  
 Isomaltitol, sweetness, 36
- J**
- Jejunum, glucose, 71
- K**
- Keratan sulfate degradation, enzymes,  
 123–125
- Kidney  
 fructokinase, 134  
 glucose-6-phosphatase, 264
- L**
- Lactase, 38, 93–100  
 adult vs. baby, 100  
 catalytic sites, 93  
 decline after birth, 94  
 development, 241  
 evolutionary questions, 111  
 first messenger, 111  
 inducible, 111–112, 232  
 lactase-phlorizin-hydrolase-mRNA, 100  
 natural decline mechanism, 245–246  
 persistent high activity, 241–246  
   lactase gene expression control  
     mechanism, 245–246  
   second messenger, 111  
   sucrase deficiency, 111  
   weaning, 97–99  
 Lactase deficiency  
   brush-border hydrolase, 107  
   diagnosis, 242  
   molecular defect, 107  
 Lactase-phlorizin-hydrolase, 94, 106  
   N-terminal amino acid, 94–95  
   polypeptide chain sequencing, 94  
 Lactitol, 44  
 Lactose, 38–40, 131, 156  
   celiac disease, 232  
   ethnic factors, 225–226  
   milk, 66  
   premature infant, 232–233  
   sweetness, 36  
 Lactose deficiency. *See* Late-onset  
   hypolactasia  
 Lactose intolerance, 93  
   diagnosis, 242–243  
   primary, 231  
   secondary, 217, 223  
 Lactose malabsorption, 217–218  
   diagnosis, 242  
 Large bowel, dietary fiber, 161  
 Large intestine, carbohydrate  
   metabolism, 157–158  
 Late-onset hypolactasia, 93, 223,  
   224–226, 241–246. *See also*  
   Lactase deficiency  
     genetics, 244  
     geographic hypothesis, 244  
     lactase gene expression control  
       mechanism, 245–246  
     prevalence, 248  
     proteins, 248  
     therapy, 244–245  
 Lipoprotein metabolism, non-insulin-  
   dependent diabetes, 172–173  
 Liver  
   fructose, 133–134  
   glycogen metabolism, 249

- Liver phosphorylase  
  clinical features, 260  
  diagnosis, 260  
  historical aspects, 260  
  treatment, 260
- Low-energy diet, 185–186
- Luminal sugar concentration, 88–90
- Lysosomal  $\alpha$ -glucosidase, 97
- Lysosomal membrane transport, 264
- Lysosomal storage disorder, 129–130
- Lysosome, mucopolysaccharide  
  degradation, 115–126
- M**
- Maltase-glucoamylase, 106
- Maltitol, 43–44
- Maltose, 40, 131  
  sweetness, 36
- Mannitol, 43
- Metabolic rate, intestinal sugar transport,  
  87
- Milk  
  lactose, 66  
  nucleotide, 66
- Milk oligosaccharide, urinary tract, 236,  
  237
- Miraculin, 48
- Monellin, 48
- Monosaccharide, 40–45  
  disaccharide hydrolysis in absorption,  
    131–132  
  intake, 69  
  secondary malabsorption, 232  
  secondary sugar intolerance, 223  
  transport and absorption defects,  
    214–215
- Mucopolysaccharide degradation,  
  lysosome, 115–126
- Mucopolysaccharidosis  
  biochemical diagnosis, 125–126  
  classification, 122  
  incidence, 126  
  treatment, 125–126
- Mucopolysaccharidosis type VI, 115, 116
- Mucosal cell proliferation  
  fatty acid, 160  
  short-chain fatty acid, 160
- Mucosal injury, brush-border hydrolase,  
  108
- Muscle, glycogen metabolism, 249
- Muscle phosphofructokinase deficiency  
  clinical features, 261  
  diagnosis, 261  
  historical aspects, 261  
  physiopathology, 261  
  treatment, 261
- Muscle phosphorylase deficiency  
  clinical features, 259  
  diagnosis, 259  
  historical aspects, 259  
  physiopathology, 259–260  
  treatment, 259–260
- N**
- $\text{Na}^+$  transport pathway, sweetness, 61–62
- New Guinea, hypertension, 211–212
- Newborn  
  galactose transport, 92  
  glucose transport, 92  
  sugar preference, 12
- Non-caloric sweetener, 25
- Non-insulin-dependent diabetes  
  carbohydrate metabolism, 172–173  
  developing population, 197–207  
    age, 201–202  
    child, 210  
    dietary change, 202–203  
    evolutionary and anthropological  
      perspective, 199  
    genetics, 200–201  
    glycemic index, 209–210  
    increased longevity, 201–202  
    lifestyle, 201–206  
    obesity, 203–204  
    onset, 210  
    physical activity, 204–205  
    risk factors, 201–206  
    stress, 206  
    thrifty gene hypothesis, 209  
    thrifty genotype, 199, 200
- insulin resistance, 172–174
- lipoprotein metabolism, 172–173
- Pacific islander, 197–207
- sucrose, 172–174

Noncentrifugal sugar, 26  
 Nonnutritive sweetener, 45–48  
 Nucleotide, milk, 66  
 Nutritional colonialism, 33  
 Nutritive sweetener, 36–45  
   U.S. total consumption, 37

**O**

Oat bran, 166, 167  
 Obesity  
   age, 180  
   appetite control, 188  
   artificial sweetener, 188–189  
   Asian Indian, 211, 211–212  
   behavioral therapy, 186–187  
   diet, 179–192  
   dietary fiber, 187–188  
   dietary intervention, 183–191  
   dietary methods, 184–191  
   drug therapy, 190  
   eating pattern, 189–190  
   energy balance, 180–182  
   exercise, 182, 185  
   food interaction thermogenic effects,  
     187  
   food therapy, 187  
   genetic factors, 180  
   goals, 184  
   hyperinsulinemia, 194  
   insulin resistance, 177  
   low-energy diet, 185–186  
   multifactorial etiology, 179  
   no change in energy diet, 184–185  
   Pacific populations, 203–204  
   pathogenesis, 180–182  
   phospholipid, 194  
   polyunsaturated fatty acid, 194  
   satiety induction, 187–188  
   surgery, 190–191  
 Oligopeptide  
   disaccharidase, 104  
   peptide hydrolase, 104  
 Oligosaccharide  
   disaccharidase, 104  
   human milk, 238  
   peptide hydrolase, 104  
 Omega 3 fatty acid, 195

**P**

Pacific islander, non-insulin-dependent  
 diabetes mellitus, 197–207  
 Peptide hydrolase  
   disaccharide, 104  
   oligopeptide, 104  
   oligosaccharide, 104  
 Phenylketonuria, 112  
 Phlorizin-hydrolase, 94  
 Phospholipid, obesity, 194  
 Phosphorylase *b* kinase deficiency  
   clinical features, 260  
   diagnosis, 260  
   historical aspects, 260  
   treatment, 260  
 Phylloolucin, 48  
 Phytic acid, 166, 167  
 Pima, diabetes, 210, 211  
 Plant cell wall, 153  
 Plasma glucose, bimodality, 177  
 Plasma transfusion, 128  
 Plasma triglyceride, coronary artery  
   disease, 169  
 Polyol, 42, 52  
 Polysaccharide, 153  
 Polyunsaturated fatty acid, obesity, 194  
 Pompe disease. *See* Type II glycogen  
   storage disease  
 Premature infant, lactose, 232–233  
 Prepro-lactase-phlorizin-hydrolase, 94  
   sequence, 95  
 Primary adult-type hypolactasia, 241–242  
 Proline uptake, 92  
 Pronase E, 56  
 Proteolytic enzyme, 56–57

**R**

Raw starch, hypoglycemia, 263  
 Resistant starch, 155–156  
 Resting metabolic rate, 180–183  
 Rodent, taste perception, 151

**S**

Saccharin, 45–46  
 Satiety, 179, 195  
   cholecystokinin, 196



- Satiety induction, obesity, 187–188
- Scheie disease, 129
- Semialkaline protease, 56
- Serotonin, 188
- Short-chain fatty acid, 158–159  
 cancer, 161–162  
 mucosal cell proliferation, 160
- Simple sugar, 154
- Skeletal muscle, triglyceride, 151
- Slavery, sugar, 7–9
- Small bowel, glucose, 70–71
- Small bowel resection, intestinal hyperplasia, 92
- Small intestine, sugar absorption, 83
- Sodium, sugar absorption, 81
- Sodium absorption, sugar absorption, 74–75
- Songbird, sucrase, 12
- Sorbitol, 42–43  
 sweetness, 36
- Starch, 155–156  
 food content, 155  
 heating effect, 155
- Stevioside, 48
- Stress, non-insulin-dependent diabetes mellitus, 206
- Sucralose, 48, 51–52
- Sucrase, songbird, 12
- Sucrase deficiency, lactase, 111
- Sucrase-isomaltase, 104–106, 112  
 activity, 132  
 biosynthesis, 104–105  
 degradation, 112  
 induction, 112  
 phylogenetic pedigree, 97  
 sorting, 104–105  
 trypsin, 112
- Sucrase-isomaltase deficiency, 132, 217–219
- Sucrose, 17, 36–37, 132  
 advantages, 29  
 alcohol, 148  
 atherosclerosis, 151  
 bulking power, 29  
 cholesterol, 140  
 coronary heart disease, 150  
 dental caries, 231  
 diabetes, 142–143  
 dose-response, 149  
 hyperactivity, 66  
 hyperlipidemia, 139–141  
 hypertriglyceridemia, 171–172  
 insulin resistance, 141–142, 176  
 non-insulin-dependent diabetes, 172–174  
 as nutrients, 132–133  
 resource use, 33, 35  
 sources, 1  
 sweetness, 36  
 triglyceride, 140, 178
- Sucrose diet, fructose transporter, 91
- Sucrose-isomaltose malabsorption, 93
- Sugar, 156–157  
 athlete's diet, 272  
 attitude toward, 30  
 brush-border transporter, 84  
 campaign against, 33, 34, 35  
 historical aspects, 1–11, 17–18  
 human milk, 233–238  
 problems due to, 35  
 slavery, 7–9  
*in vivo* human absorption, 69–78  
 world price, 23, 24, 27
- Sugar absorption  
 completeness, 77–78  
 regulation, 84–88  
 small intestine, 83  
 sodium absorption, 74–75  
 water absorption, 74–75
- Sugar alcohol, 42  
 malabsorption, 156
- Sugar beet, 9–11  
 alternative uses, 26  
 artificial subsidies, 30  
 discovery, 9  
 historical aspects, 9–10  
 resource requirements, 31
- Sugar cane, 1–9, 17  
 alternative crop, 30–31  
 alternative uses, 26  
 botanical characteristics, 2  
 development, 1–2  
 migration, 2–7, 17–18  
 mill, 4–5  
 resource requirements, 31
- Sugar digestion, defects, 103–109

- Sugar field labor, 31
  - Sugar-induced diarrhea, 221–228
    - breast feeding, 230
  - Sugar industry
    - bulk handling, 29
    - increased yield, 29
    - land use, 29
    - mechanical harvesting, 29
    - technological development, 29
  - Sugar intolerance, 221–228
    - breath tests, 227
    - classification, 222
    - clinical features, 221–222
    - diagnosis, 227–228
    - genetic forms, 225
    - management, 228
    - primary, 224
    - secondary, 222–224
    - underlying gastrointestinal disease, 222–224
  - Sugar metabolism, disorders, 213–220
  - Sugar production
    - Australia, 29
    - Thailand, 30
  - Sugar substitute, 25
  - Sweet polyhydric alcohol, 42
  - Sweet receptor
    - behavioral approaches, 56–57
    - biochemical approaches, 55–56
    - electrophysiological approaches, 56–57
    - immunological approaches, 56
    - multiple sites, 57–59
    - multiple types, 57
    - nature, 56
    - psychophysical approaches, 57–61
  - Sweet taste
    - diabetes, 66
    - receptor, 55–64
    - transduction mechanisms, 55–64
  - Sweet-tasting molecule, 55
  - Sweetener
    - cross-adaptation, 58
    - types, 1, 2
  - Sweetness
    - cAMP transport, 62–64
    - desire, 1
    - K<sup>+</sup> transport, 62–64
    - multidimensional taste quality, 59–61
    - Na<sup>+</sup> transport pathway, 61–62
- T**
- Taste modifier, 57
  - Taste perception, rodent, 151
  - Taste sense, drugs affecting, 67
  - Texture, 188
  - Thailand, sugar production, 30
  - Thaumatococcus, 48
  - Thermic effect of exercise, 180–183
  - Thermic effect of feeding, 180–183
  - Transmucosal potential, glucose, 72, 73
  - Trehalase, 107
    - monoclonal antibodies against, 113
  - Trehalase deficiency, 113, 219
  - Trehalose, 14
  - Triglyceride
    - skeletal muscle, 151
    - sucrose, 140, 178
  - Trypsin, sucrase-isomaltase, 112
  - Twenty-four hour energy expenditure, 180–183
  - Type I glycogen storage disease
    - biochemical defect, 253
    - clinical features, 253–254
    - functional tests, 253–254
    - historical aspects, 251–252
    - physiopathology, 253
    - treatment, 254
  - Type II glycogen storage disease
    - clinical manifestations, 254–255
    - enzymic defect, 256
    - historical aspects, 254
    - morbidity, 255–256
    - physiopathology, 256
    - treatment, 256
  - Type III glycogen storage disease
    - clinical features, 256–257
    - diagnosis, 257
    - functional tests, 257
    - genetic heterogeneity, 257
    - historical aspects, 256
    - treatment, 257
  - Type IV glycogen storage disease
    - clinical features, 257–258
    - diagnosis, 258
    - glycogen abnormality, 258
    - historical aspects, 257–258
    - pathogenesis, 258
    - treatment, 258

Type V glycogen storage disease  
 clinical features, 259  
 diagnosis, 259  
 historical aspects, 259  
 physiopathology, 259–260  
 treatment, 259–260

Type VI glycogen storage disease  
 clinical features, 260  
 diagnosis, 260  
 historical aspects, 260  
 treatment, 260

Type VII glycogen storage disease  
 clinical features, 261  
 diagnosis, 261  
 historical aspects, 261  
 physiopathology, 261  
 treatment, 261

**U**

Uric acid, fructose, 149  
 Urinary tract infection, milk  
     oligosaccharide, 236, 237  
 Uronic acid, 115

**V**

Very low density lipoprotein,  
     hyperinsulinemia, 169  
 Vitamin, athlete's diet, 273

**W**

Waist/hip ratio, 195  
 Water absorption  
     fructose, 81  
     sugar absorption, 74–75  
 Weaning, lactase, 97–99  
 Western Africa, hypertension, 211–212  
 Wheat bran, 166  
 World sugar economy, 18–26  
     trade expansion, 18  
 World sugar stock, 28  
 World sugar trade, 20–22  
     consumption, 19, 27  
     international agreements, 23–25  
     medical size, 22  
     price, 27  
     production, 20, 21  
     protection, 19

**X**

Xylitol, 44  
     sweetness, 36

**Z**

Zinc, athlete's diet, 273